S83777 |
TAPI-1 |
源葉(MedMol) | 98% |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.002 ml | 10.008 ml | 20.016 ml |
5 mM | 0.4 ml | 2.002 ml | 4.003 ml |
10 mM | 0.2 ml | 1.001 ml | 2.002 ml |
50 mM | 0.04 ml | 0.2 ml | 0.4 ml |
- 提示:詳情請下載說明書。
- 產(chǎn)品描述: TAPI-1 is a TACE (ADAM17) inhibitor and blocks the shedding of several cell surface proteins. TAPI-1 is also a metalloproteinase (MMP) inhibitor
- 靶點(diǎn): TACE (ADAM17), MMP;MMP
- 體外研究:
TAPI-1 (1 μM for 30 min) increases cell viability in LPS-treated HK-2 cells. TAPI-1 attenuates oxidative stress and inflammatory cytokines LPS treatment significantly induces renal IL-6 and TNFα mRNA expression, while these changes is attenuated with TAPI-1 pretreatment in LPS-treated HK-2 cells. Cell Viability Assay Cell Line: LPS-treated HK-2 cells Concentration: 1 μM Incubation Time: 30 minutes (pre-treated) Result: Increased cell viability.
- 參考文獻(xiàn):
1. Bae EH, et al. Tumor necrosis factor α-converting enzyme inhibitor attenuates lipopolysaccharide-induced reactive oxygen species and mitogen-activated protein kinase expression in human renal proximal tubule epithelial cells. Korean J Physiol Pharmacol. 2018 Mar;22(2):135-143. 2. Moss ML, et al. Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. Mediators Inflamm. 2017;2017:9673537.
- 溶解性: soluble in DMSO
- 保存條件: -20℃
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 2.002 ml 10.008 ml 20.016 ml 5 mM 0.4 ml 2.002 ml 4.003 ml 10 mM 0.2 ml 1.001 ml 2.002 ml 50 mM 0.04 ml 0.2 ml 0.4 ml
- 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:
本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:
質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)